Clinical Trial Update: Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection [Phase 2]

View source ↗

Summary

Phase 2 trial update on combinations of AL-335, Odalasvir and Simeprevir for chronic hepatitis C; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• AL-335 (AL-335)
• Odalasvir (odalasvir)
• Simeprevir (simeprevir)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2019-01-22